Description: The SPACE study evaluates innovative digital tools designed to assess navigation and gait, aiming to differentiate individuals across the cognitive spectrum. These tools will be compared to traditional tests, like the Montreal Cognitive Assessment (MoCA), and fluid biomarkers. The navigation tool, a tablet application, and the ZurichMOVE gait sensor system focus on spatial and gait deficits, which are early indicators of Alzheimer’s Disease (AD), vascular dementia (VaD), and Mild Cognitive Impairment (MCI).
Current diagnostics, including invasive biomarkers and less sensitive neuropsychological tests, face limitations in early detection. Our digital tools target spatial navigation deficits, enhancing early detection accuracy for AD and aiding differentiation from VaD. This approach offers a cost-effective, non-invasive screening method, reducing unnecessary diagnostics and improving early intervention opportunities.
Through the SPACE study, we aim to validate these assessments for widespread use, ultimately improving patient outcomes through timely detection and intervention.
